Rentschler Biopharma, Germany-based biopharmaceuticals manufacturer with a U.S. headquarters in Milford, is undergoing a major executive transition as the firm’s CEO and chief operating officer have stepped down and an interim leader has been named.
Get Instant Access to This Article
Subscribe to Worcester Business Journal and get immediate access to all of our subscriber-only content and much more.
Rentschler Biopharma, Germany-based biopharmaceuticals manufacturer with a U.S. headquarters in Milford, is undergoing a major executive transition as the firm’s CEO and chief operating officer have stepped down and an interim leader has been named.
The departure of Benedikt von Braunmühl, Rentschler’s former CEO, was announced in a Tuesday press release from the manufacturer. Braunmühl originally joined Rentschler in late 2023 from his role as CEO of HMNC Brain Health in Munich, Germany.
“I want to thank all of my colleagues for their dedication and the strong collaboration across all functions and sites. Rentschler Biopharma is well positioned for a successful future, and I wish the entire team continued success on this journey,” von Braunmühl said in the release.
Succeeding von Braunmühl is interim CEO Uwe Buecheler, who has served as vice chairman of the Rentschler’s supervisory board since 2024. Buecheler’s appointment comes as the manufacturer plans to implement a new corporate strategy to support long-term growth and value creation.
“Rentschler Biopharma is currently in a strong operational and economic position. Building on the scale-up of our production capacity, our outstanding development capabilities, and successful efficiency improvements across our sites, we are leading Rentschler Biopharma into the next phase of development, one that is even more strongly focused on client satisfaction, proximity to clients, and business expansion,” Buecheler said in the release.
Along with von Braunmühl’s departure, Rentschler’s COO Christiane Bardroff is set to leave the company for a new professional opportunity in the first quarter. As of Tuesday morning, Bardroff’s LinkedIn profile had not been updated to reflect a new position.
Rentschler has selected Bardroff’s replacement, with an announcement to come.
“With her focus on operational excellence, quality, digitalization, and automation, she has provided important impetus for our company’s continued advancement. The supervisory board sincerely thanks Ms. Bardroff for her dedication, commitment, and trustful collaboration and wishes her every success and all the very best on the journey ahead,” Nikolaus Rentschler, chairman of the supervisory board, said in the release.
Rentschler’s C-suite turnover follows the manufacturer’s securing a contract to make in Milford a new blood coagulation treatment created by VarmX, a biotech firm out of the Netherlands.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
